Dyadic International (DYAI) Cash from Investing Activities (2018 - 2026)
Dyadic International (DYAI) posted Cash from Investing Activities of $1.3 million for Q1 2026, up 170.46% sequentially from $468159.0 in Q4 2025, and up 162.64% YoY from $482104.0 in Q1 2025.
Dyadic International (DYAI) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Dyadic International has reported Cash from Investing Activities for 9 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 162.64% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $866177.0 (up 217.17% YoY) and the FY2025 annual result came in at $82085.0, up 104.37% from the prior year.
- Cash from Investing Activities grew to $1.3 million in Q1 2026 per DYAI's latest filing, from $468159.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $3.5 million in Q3 2023 and troughed at -$2.5 million in Q2 2024.
- A 5-year average of $267802.6 and a median of $93442.0 in 2025 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 3598.76% in 2024, down 320.55% in 2024.
- Over 5 years, Cash from Investing Activities stood at $617918.0 in 2022, then slumped by 94.47% to $34154.0 in 2023, then surged by 3598.76% to $1.3 million in 2024, then tumbled by 62.94% to $468159.0 in 2025, then soared by 170.46% to $1.3 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $1.3 million, $468159.0, and $93442.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.27 Mn |
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 468,159.00 |
| Dec 31, 2025 | 468,159.00 |
| Sep 30, 2025 | 93,442.00 |
| Sep 30, 2025 | 93,442.00 |
| Jun 30, 2025 | -961,620.00 |
| Jun 30, 2025 | -961,620.00 |
| Mar 31, 2025 | 482,104.00 |
| Mar 31, 2025 | 482,104.00 |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | -11,977.00 |
| Sep 30, 2024 | -11,977.00 |
| Jun 30, 2024 | -2.47 Mn |
| Jun 30, 2024 | -2.47 Mn |
| Mar 31, 2024 | -654,907.00 |
| Mar 31, 2024 | -654,907.00 |
| Dec 31, 2023 | 34,154.00 |
| Dec 31, 2023 | 34,154.00 |